criteria for glp-1 If you're covered by the State Health Benefit Plan (SHBP) and take a weight-loss medication (like Wegovy or Zepbound), a change is coming. Starting February 1, 2026, SHBP will require these Eligibility criteria specified in GLP-1

-30% Fat: Specifically targets stubborn visceral fat

It is essential to know what to expect and when to seek help

GLP-1 receptors are not only expressed in the pancreas and gastrointestinal tract, but also in the brain, where they influence neuronal survival and metabolism [9]

But, if you have access to both, we would recommend the following: If your health would benefit from the higher percentage weight loss (15-20%) of Zepbound / tirzepatide, and you have not had a cardiac event, Zepbound offers modestly more weight loss with fewer side effects

Persistent fatigue despite adequate sleep and nutrition suggests potential underdosing or inadequate caloric intake

Finally, a cohort study Trusted Source PubMed Central Go to source investigated the safety and efficacy of GLP-1 analogs for comorbid obesity in a small number of IBD patients